Cognition Therapeutics (CGTX) Short Interest Ratio & Short Volume $0.47 +0.01 (+1.89%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cognition Therapeutics Short Interest DataCognition Therapeutics (CGTX) has a short interest of 2.11 million shares, representing 6.27% of the float (the number of shares available for trading by the public). This marks a 847.04% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 1.66 million shares to cover all short positions.Current Short Interest2,110,000 sharesPrevious Short Interest222,800 sharesChange Vs. Previous Month+847.04%Dollar Volume Sold Short$959,839.00Short Interest Ratio0.3 Days to CoverLast Record DateFebruary 28, 2025Outstanding Shares41,548,000 sharesFloat Size33,670,000 sharesShort Percent of Float6.27%Today's Trading Volume11,514 sharesAverage Trading Volume1,659,725 sharesToday's Volume Vs. Average1% Short Selling Cognition Therapeutics? Sign up to receive the latest short interest report for Cognition Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCGTX Short Interest Over TimeCGTX Days to Cover Over TimeCGTX Percentage of Float Shorted Over Time Remove Ads Cognition Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/28/20252,110,000 shares $959,839.00 +847.0%6.3%0.3 $0.45 2/15/2025222,800 shares $131,474.28 -57.5%0.7%0 $0.59 1/31/2025523,900 shares $378,779.70 -16.2%1.6%0.1 $0.72 1/15/2025624,900 shares $441,491.85 -65.5%1.8%0.1 $0.71 12/31/20241,810,000 shares $1.27 million +23.1%5.1%0.3 $0.70 12/15/20241,470,000 shares $702,660.00 -45.2%4.2%0.2 $0.48 11/30/20242,680,000 shares $1.08 million +270.7%7.7%1.9 $0.40 11/15/2024723,000 shares $333,447.60 -11.4%2.1%0.6 $0.46 10/31/2024815,700 shares $385,091.97 +66.2%2.4%1.5 $0.47 10/15/2024490,700 shares $206,584.70 -7.7%1.5%0.4 $0.42 Get the Latest News and Ratings for CGTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/30/2024531,400 shares $249,014.04 -25.1%1.6%0.5 $0.47 9/15/2024709,900 shares $426,010.99 -22.4%2.1%0.7 $0.60 8/31/2024914,900 shares $650,859.86 +41.3%2.7%0.9 $0.71 8/15/2024647,500 shares $415,695.00 -63.4%1.9%0.7 $0.64 7/31/20241,770,000 shares $1.77 million +724.0%5.3%2 $1.00 7/15/2024214,800 shares $412,416.00 +3.2%0.6%1.5 $1.92 6/30/2024208,100 shares $345,446.00 +15.2%0.6%1.4 $1.66 6/15/2024180,700 shares $392,119.00 -14.2%0.5%1.3 $2.17 5/31/2024210,600 shares $410,670.00 +71.9%0.6%1.3 $1.95 5/15/2024122,500 shares $238,875.00 -28.9%0.4%0.7 $1.95 4/30/2024172,300 shares $329,093.00 -21.8%0.6%0.9 $1.91 4/15/2024220,300 shares $420,773.00 +46.7%0.7%1.1 $1.91 3/31/2024150,200 shares $273,364.00 -34.2%0.5%0.7 $1.82 3/15/2024228,100 shares $415,142.00 +79.9%1.0%1.1 $1.82 2/29/2024126,800 shares $262,476.00 +26.2%0.6%0.5 $2.07 2/15/2024100,500 shares $198,990.00 -30.9%0.5%0.5 $1.98 1/31/2024145,400 shares $330,058.00 +24.0%0.7%0.8 $2.27 1/15/2024117,300 shares $236,946.00 +65.0%0.5%0.6 $2.02 12/31/202371,100 shares $131,535.00 -52.9%0.3%0.4 $1.85 12/15/2023150,900 shares $307,836.00 -23.6%0.7%0.9 $2.04 11/30/2023197,500 shares $219,225.00 -17.8%0.9%1.7 $1.11 11/15/2023240,200 shares $252,210.00 -19.1%1.1%2.4 $1.05 10/31/2023296,800 shares $332,416.00 +368.9%1.3%3.1 $1.12 10/15/202363,300 shares $70,896.00 -34.3%0.3%1.6 $1.12 9/30/202396,300 shares $138,672.00 +16.3%0.4%2.3 $1.44 9/15/202382,800 shares $104,328.00 -4.5%0.4%0.7 $1.26 8/31/202386,700 shares $134,385.00 +5.0%0.4%0.7 $1.55 8/15/202382,600 shares $123,074.00 -21.1%0.4%0.5 $1.49 7/31/2023104,700 shares $173,802.00 -36.2%0.5%0.6 $1.66 7/15/2023164,100 shares $283,893.00 -33.7%0.8%1 $1.73AI Boom Takes a Shocking Turn… (Ad)AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a brand-new report…The #1 AI Coin for 2025 (Click here to access it now) 6/30/2023247,600 shares $453,108.00 +131.2%1.2%1.6 $1.83 6/15/2023107,100 shares $320,229.00 +75.0%0.5%1.2 $2.99 5/31/202361,200 shares $125,460.00 -4.8%0.3%0.7 $2.05 5/15/202364,300 shares $109,953.00 -8.8%0.3%0.9 $1.71 4/30/202370,500 shares $125,490.00 -15.0%0.3%1.1 $1.78 4/15/202382,900 shares $147,562.00 -35.7%0.4%1.2 $1.78 3/31/2023128,900 shares $255,222.00 +56.6%0.6%1.7 $1.98 3/15/202382,300 shares $135,795.00 -3.1%0.4%1.1 $1.65 2/28/202384,900 shares $135,840.00 +43.9%0.5%0.9 $1.60 2/15/202359,000 shares $110,330.00 +1.0%0.4%0.3 $1.87 1/31/202358,400 shares $115,048.00 -34.9%0.3%0.3 $1.97 1/15/202389,700 shares $199,134.00 -16.8%0.5%0.5 $2.22 12/30/2022107,800 shares $226,380.00 -32.9%0.7%0.6 $2.10 12/15/2022160,600 shares $420,772.00 -49.3%1.1%0.8 $2.62 11/30/2022316,500 shares $1.11 million +136.2%2.1%1.6 $3.51 11/15/2022134,000 shares $194,300.00 +116.1%0.9%1.1 $1.45 10/31/202262,000 shares $110,360.00 +98.1%0.4%0.7 $1.78 10/15/202231,300 shares $56,966.00 -40.8%0.2%0.1 $1.82 9/30/202252,900 shares $100,510.00 +8.4%0.3%0.1 $1.90 9/15/202248,800 shares $91,256.00 +15.4%0.4%0.1 $1.87 8/31/202242,300 shares $86,715.00 +10.7%0.3%0.1 $2.05 8/15/202238,200 shares $76,400.00 +144.9%0.3%0.1 $2.00 7/31/202215,600 shares $29,484.00 +31.1%0.1%0 $1.89 7/15/202211,900 shares $23,919.00 -57.2%0.1%0.3 $2.01 6/30/202227,800 shares $58,658.00 +1,753.3%0.2%0.6 $2.11 6/15/20221,500 shares $2,715.00 -42.3%0.0%0 $1.81 5/31/20222,600 shares $6,812.00 +36.8%0.0%0 $2.62 5/15/20221,900 shares $5,548.00 -88.8%0.0%0 $2.92 4/30/202217,000 shares $47,090.00 +34.9%0.1%0.3 $2.77 4/15/202212,600 shares $36,540.00 +44.8%0.1%0.2 $2.90 3/31/20228,700 shares $23,925.00 +52.6%0.1%0.1 $2.75 3/15/20225,700 shares $14,307.00 -54.0%0.1%0.1 $2.51 2/28/202212,400 shares $38,068.00 +2.5%0.1%0.2 $3.07 2/15/202212,100 shares $44,165.00 +86.2%0.1%0.1 $3.65 1/31/20226,500 shares $28,600.00 -78.9%0.1%0.1 $4.40 1/15/202230,800 shares $192,500.00 +33.9%0.3%0.4 $6.25 12/31/202123,000 shares $145,360.00 No Change0.2%0.3 $6.32 CGTX Short Interest - Frequently Asked Questions What is Cognition Therapeutics' current short interest? Short interest is the volume of Cognition Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 28th, investors have sold 2,110,000 shares of CGTX short. 6.27% of Cognition Therapeutics' shares are currently sold short. Learn More on Cognition Therapeutics' current short interest. What is a good short interest percentage for Cognition Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.27% of Cognition Therapeutics' floating shares are currently sold short. Is Cognition Therapeutics' short interest increasing or decreasing? Cognition Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 2,110,000 shares, an increase of 847.0% from the previous total of 222,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cognition Therapeutics' float size? Cognition Therapeutics currently has issued a total of 41,548,000 shares. Some of Cognition Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cognition Therapeutics currently has a public float of 33,670,000 shares. How does Cognition Therapeutics' short interest compare to its competitors? 6.27% of Cognition Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cognition Therapeutics: Theratechnologies Inc. (0.25%), IGM Biosciences, Inc. (7.04%), Scilex Holding (3.48%), vTv Therapeutics Inc. (1.63%), InterCure Ltd. (0.11%), Aligos Therapeutics, Inc. (27.36%), Genenta Science S.p.A. (0.01%), Aerovate Therapeutics, Inc. (20.57%), ESSA Pharma Inc. (1.71%), Metagenomi, Inc. (12.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), MicroStrategy Incorporated ($6.56 billion), Apollo Global Management, Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Co. ($4.45 billion), Capital One Financial Co. ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks. What does it mean to sell short Cognition Therapeutics stock? Short selling CGTX is an investing strategy that aims to generate trading profit from Cognition Therapeutics as its price is falling. CGTX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cognition Therapeutics? A short squeeze for Cognition Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CGTX, which in turn drives the price of the stock up even further. How often is Cognition Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CGTX, twice per month. The most recent reporting period available is February, 28 2025. More Short Interest Resources from MarketBeat Related Companies THTX Short Interest IGMS Short Interest SCLX Short Interest VTVT Short Interest INCR Short Interest ALGS Short Interest GNTA Short Interest AVTE Short Interest EPIX Short Interest MGX Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CGTX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
